Background: Myeloid-derived suppressor cells (MDSCs) are elevated in glioblastoma (GBM) patient circulation, present in tumor tissue, and associated with poor prognosis. While low-dose chemotherapy reduces MDSCs in preclinical models, the use of this strategy to reduce MDSCs in GBM patients has yet to be evaluated.
Introduction
Glioblastoma (GBM) is the most common primary malignant brain tumor, with an annual incidence of 11,000 cases in the U.S. and a median survival of 14-18 months despite aggressive therapies [1] [2] [3] [4] [5] . Currently, standard of care includes maximal safe surgical resection followed by concomitant radiation and chemotherapy with temozolomide 1 . In nearly 100% of cases, this approach fails, resulting in a recurrent tumor with limited therapeutic options. Few therapies are FDA-approved for patients with recurrent GBM, including lomustine, bevacizumab, carmustine wafers, and tumor-treating fields, none of which have demonstrated a marked improvement in overall survival [6] [7] [8] [9] . Multiple other cancers have faced similar obstacles to effective treatment, but this has been recently overcome with the use of immune-modulating therapies, and as a consequence, there is interest in trying to modify the immune system in GBM. Several immunomodulatory approaches are currently under clinical evaluation, including the use of immune checkpoint inhibitors, oncolytic viruses, dendritic cell vaccines, and CAR-T cell approaches 10 , but the wellappreciated immunosuppressive nature of GBM has proven difficult to overcome [11] [12] [13] [14] [15] .
A hallmark of GBM immunosuppression is the appearance of circulating myeloid-derived suppressor cells (MDSCs) at higher levels than in many other cancers 11, 13, [16] [17] [18] [19] [20] . This heterogeneous cell population is activated upon injury and in many cancers, where MDSCs inhibit cytotoxic immune cell populations and contribute to overall immune suppression [21] [22] [23] [24] [25] . In multiple solid tumor models and clinical trials, elevated peripheral MDSC levels have been correlated with a more immunosuppressive phenotype, as well as with tumors that were refractory to immuneactivating therapies, including immune checkpoint inhibitors 26, 27 . We previously observed that GBM patients with a better prognosis had reduced MDSCs in their tumors as well as in their peripheral circulation 13, 22 . Previous studies have demonstrated that MDSCs in multiple tumor types can be reduced via low-dose chemotherapies [28] [29] [30] . We recently found that this could be achieved in pre-clinical GBM mouse models via 5-fluorouracil , an antimetabolite drug that impacts both RNA and DNA synthesis via its inhibition of thymidylate synthase. Utilizing a metronomic low-dose 5-FU strategy, we were able to reduce circulating MDSCs, increase intratumoral activated T cell populations, and prolong survival 11 . Based on these pre-clinical observations, we sought to test this approach in recurrent GBM patients using an orally bioavailable 5-FU prodrug, capecitabine, combined with standard-of-care bevacizumab, an antiangiogenic agent. The addition of bevacizumab, an anti-VEGF (vascular endothelial growth factor) antibody, was used to ensure that patients received standard therapy for recurrent GBM.
In this phase 0/1 dose-escalation trial, our objective was to assess the ability of capecitabine to reduce circulating and tumoral MDSCs and to determine the safety/toxicity profile of capecitabine alone and in combination with bevacizumab in this patient population. Based on the hypothesis that this treatment approach would reduce immune suppression, we also analyzed circulating immune cells via flow cytometry and evaluated the immune profile of treated tumors with mass cytometry time of flight (CyTOF).
Results

Phase 0/1 clinical trial demographics
Patient accrual began in October 2016. To target MDSCs, we assessed the efficacy of escalating low doses of metronomic capecitabine with a fixed, standard dose of bevacizumab in a clinical trial approved by the Cleveland Clinic IRB (NCT02669173). Once GBM recurrence was identified on MRI, study-specific informed consent was obtained. Capecitabine was given 5-7 days prior to operation and then continued in 28-day cycles with periodic blood draws to assess peripheral blood immune cell populations over the course of the trial (Figure 1) . A total of 12 patients were enrolled initially, with one patient removed from all aspects of the study after their resection specimen identified pseudoprogression. The demographics of the 11 evaluable patients are summarized in Table 1 . The median age at diagnosis was 58 years; 7 patients were enrolled at the time of their first progression, and the remaining 4 patients were enrolled at their second progression. Surgical therapy at diagnosis included biopsy only (2 patients), biopsy with laser ablation (1 patient), and surgical resection (8 patients). All patients then received standard-of-care radiation with concurrent and adjuvant temozolomide. Additional therapies prior to trial enrollment included other chemotherapies (4 patients (2 had received lomustine and 2 received tesevatinib a, a multi-targeted tyrosine kinase inhibitor)), tumor-treating fields (1 patient), and immunotherapies (3 patients). The 3 patients who previously received immunotherapy included 2 patients who failed anti-LAG3 treatment and 1 patient who received the SurVaxM vaccine. Five patients had MGMT-methylated GBMs and 1 of these had an IDH mutation. These 3 patients demonstrated no remarkable differences in immune populations compared to the others on the trial. Expanded patient details, including molecular markers and other disease-management paradigms, are provided in Supplemental Table 1 . Patients received capecitabine in 3 dose cohorts: 150 mg bid (4 patients), 300 mg bid (3 patients), and 450 mg bid (4 patients).
Clinical outcomes
The median follow-up time was 10.7 months (range 3 to 29 months). The median progressionfree survival (PFS) was 5.8 months (ranging from 1.8 months to >27 months, Figure 2A) , with 45% (5 out of 11 patients) achieving a 6-month PFS. The median overall survival (OS) was 11.5 months from trial enrollment (ranging from 3.0 to >28.0 months, Figure 2B ). The number of patients still active on trial at the time of manuscript submission is 2 out of 11 (18%), and the number of patients alive is 3 out of 11 (27%). The median follow-up time was 10.7 months with a range of 3-29 months. The median PFS was 7.25 months for patients receiving capecitabine at 150 mg bid, 5.5 months for those receiving 300 mg bid, and 7.35 months for those receiving 450 mg bid. The median OS was 16.6 months for patients receiving capecitabine at 150 mg bid, with one patient still on study; 11.5 months at 300 mg bid, and 9.8 months at 450 mg bid, with one patient still on the study and 1 patient alive but taken off the study due to progressive disease.
Tolerability of metronomic low-dose capecitabine therapy in recurrent GBM patients
Capecitabine at all three doses administered in combination with bevacizumab was generally well tolerated, with one treatment-related serious adverse effect (event possibly, probably, or definitely related to treatment)grade 5 perforated diverticulum ( Table 2 ). This patient suffered the event after going off study but within 30 days of completion of the study treatment. No other grade 4 or 5 events occurred. Tables 2 and 3 summarize the treatment-related adverse events, which included one patient each with grade 3 thromboembolism and dyspnea. One patient in the 450 mg bid cohort experienced grade 3 anemia approximately 2.5 months into the trial and was dosereduced to 300 mg bid. Other side effects were grade 1 and 2 and included fatigue (4 patients), hypertension (3 patients), nausea and vomiting (2 patients), and a small intracranial hemorrhage that required no intervention (1 patient).
Daily oral capecitabine reduced the expected increase in MDSCs post-surgical resection
Peripheral blood MDSC concentrations were evaluated via flow cytometry (Supplemental Figure   1A ) before treatment, during surgical resection and post-surgical resection on a per-patient basis to visualize trends in MDSC changes over time 13 (Figure 3A) . Patients in the 300 mg bid and 450 mg bid capecitabine treatment arms had a reduction in MDSCs post-surgery, which was not observed in the 150 mg bid arm ( Figure 3A) . As a comparison, a longitudinal analysis of newly diagnosed GBM patients conducted in a separate, contemporaneous study showed a continued increase in MDSCs over time after surgical resection ( Figure 3A) . This increase in peripheral blood MDSCs post-surgery has been attributed to surgical intervention in multiple cancer types 16, 23, 31, 32 and occurs in untreated patients prior to surgical resection ( Figure 3A) . These analyses allowed us to identify a relative reduction in peripheral MDSCs post-surgical resection in the 300 and 450 mg bid capecitabine cohorts in 6 out of 7 patients ( Figure 3A) . Of note, patient 3 in the 450 mg bid capecitabine treatment cohort (the only patient who did not have a reduction in peripheral MDSCs post-surgery) was noted to have multifocal GBM at the time of recurrence and enrollment in the trial. The distal site of recurrence was not resected, and the patient progressed To further determine the changes in tumor immune profiles associated with systemic capecitabine treatment, we analyzed GBM tissue from patients treated with capecitabine 5-7 days before surgery via CyTOF, which we previously used to identify immune shifts associated with GBM patient prognosis 13 . This immune panel consisted of 28 key cell surface immune system markers (Supplemental Figure 2A) . In the CD45+ cell fraction from cryopreserved single-cell tumor suspensions of newly diagnosed GBM patients, recurrent GBM patients, and GBM patients treated with capecitabine in our trial (300 mg and 450 mg bid, Figure 4A ), we identified 29 unique immune populations in an unbiased manner by using t-distributed stochastic neighbor embedding 
Discussion
Findings from this study indicate that low-dose capecitabine pre-operatively and post-operatively in combination with bevacizumab is well tolerated at all doses, with an acceptable side-effect profile. While there is no control arm in this phase 0/1 trial, preliminary findings indicate that PFS and OS were comparable to historical controls 1, 7 . Comparisons of the immune populations between the capecitabine-treated groups revealed that 300 mg bid was the optimal capecitabine dose that led to maximal decreases in circulating MDSCs in a subset of patients without impacting lymphoid populations needed for an anti-tumor immune response. Finally, CyTOF analyses revealed that 5-7 days of priming the immune system with low-dose capecitabine treatment at 300 mg bid and 450 mg bid enhanced the anti-tumor immune cell populations within the tumor, including CD8 + effector memory cells and NK cells. However, these results are underpowered to resolve the complete effects of capecitabine on the tumor immune responses of the patients and support the expansion of this strategy to a larger, controlled clinical trial utilizing 300 mg bid capecitabine.
While patients on this trial received both capecitabine and bevacizumab, the tumor immune profile was analyzed on surgical samples obtained before bevacizumab treatment. Therefore, the observed intratumoral effects of capecitabine could not have been a result of bevacizumab treatment. Furthermore, although circulating MDSC levels were analyzed while patients were on bevacizumab and capecitabine, the noted MDSC changes began to occur before the initiation of bevacizumab. The decreasing MDSC levels also occurred in a capecitabine dose-dependent manner, making it unlikely that bevacizumab played a significant role. However, the potential adjuvant effects of bevacizumab on circulating immune populations cannot be inferred from these results.
In this trial, we employed an emerging single-cell phenotyping approach, CyTOF, to gain insight into comprehensive immune signatures within GBM. By integrating these data with a machinelearning approach 33 , we identified a potential increase in immune activation after capecitabine treatment. Recently, utilization of next-generation technology to enhance clinical trials identified key changes between responders and non-responders [34] [35] [36] . For example, in three recent GBM immunotherapy clinical trials, single-cell RNA-sequencing, CyTOF, and T cell receptor repertoire/clonality analyses demonstrated changes in the immune microenvironment as a result of therapy, immune alterations as a result of the dynamics of clonal tumor cell evolution, and specific immune signatures associated with response [34] [35] [36] . Taken together, these approaches demonstrate insight that can be provided by these immune-monitoring approaches.
The dosing of chemotherapy agents has historically focused on the maximal tolerated dose to increase anti-tumor effects. In many cases, these high doses are associated with profound bone marrow toxicity, eliminating both pro-and anti-tumor immune cells 28, [37] [38] [39] [40] .
However, chemotherapies such as 5-fluorouracil and gemcitabine differentially impact the immune system at low doses, and this has recently been observed with temozolomide 12, 16, 29, 41 . By reducing the dose of these standard chemotherapies, it may be possible to reduce a subset of immune cells that drive immune suppression with little negative impact on anti-tumor immune cell concentration or function. While the mechanisms of action are not well elucidated, this effect may be due to differential sensitivity and/or different proliferation rates. In this trial, the capecitabine dose (300 mg bid) that led to the maximal decrease in peripheral immunosuppressive MDSCs was four-to five-fold lower than that used in colorectal cancer (1250 mg bid) 42 and pancreatic cancer (2000 mg bid) 43 , and increasing the dose of drug (to 450 mg bid) did not offer further reductions in immunosuppressive MDSCs. Importantly, these lower doses of capecitabine increased intratumoral immune-activating cell subsets, suggesting that these doses were more specific for immunosuppressive compartments. Previously our preclinical models have illustrated this strategy of selective MDSC inhibition 11 , and with the results of this trial, we have validated this approach in humans with recurrent GBM. Combined, these data suggest an optimally administered dosage of 300 mg bid capecitabine, with higher doses yielding no significant gains in MDSC reduction while increasing the propensity for side effects and potential global immune suppression. Future studies should now investigate this approach in newly diagnosed GBM patients at the 300 mg bid dose, based on our observation that newly diagnosed patients have an overall increase in MDSC levels over time (which low-dose capecitabine was demonstrated to reduce, Figure 3A) .
This study assessed the paradigm of an immunomodulatory approach based not on activating T cells but rather relieving immune suppression in the tumor microenvironment by targeting MDSCs.
However, targeting MDSCs as a monotherapeutic strategy may not be sufficient to obtain a durable clinical response. Ongoing approaches are exploring immune-activating strategies in GBM, including immune checkpoint inhibitors, oncolytic viruses, CAR-T cells, and vaccine approaches. Unfortunately, none of these approaches have yet to demonstrate durable immune responses and convincing evidence of patient benefit 10, 44 . One possible explanation for this lack of clinical benefit is that the treatments tested have yet to overcome the inherent immunesuppressive nature of GBM. Therefore, future studies should be designed to utilize capecitabine in combination with other immune checkpoint inhibitors such as anti-PD1 therapy. This design is based on the observation that while CTLA-4 was reduced upon treatment, we also observed that PD-1 increased, possibly due to immune activation, in capecitabine-treated patients, making it a practical combinatorial treatment strategy to further enhance the anti-tumor immune response (Supplemental Figure 5-7) . The immunobiology of GBM is complex, and given the negative results of other clinical immunotherapy trials in GBM, our findings suggest that any successful GBM immunotherapy strategy will likely require a synergistic approach that includes targeting of the immune suppressive/inhibitory effects of MDSCs along with utilization of immune activation strategies to overcome the global GBM-induced immunosuppression phenomenon.
Methods
Clinical study design
Clinical Trial Design: This trial is a phase 0/1 study of low-dose capecitabine and bevacizumab in patients with recurrent GBM (ClinicalTrials.gov #NCT02669173). Once GBM recurrence was identified on MRI, study-specific informed consent was obtained. Capecitabine was given 5-7 days prior to a clinically indicated surgical resection and then continued post-operatively in 28day cycles with periodic blood draws to assess peripheral blood immune cell populations over the course of the trial (Figure 1) . Patients were included if they had a recurrent histologically confirmed WHO grade 4 glioma for which a clinically indicated resection was planned. All subjects were at least 18 years of age, had no prior treatment with capecitabine or bevacizumab, and had a Karnofsky Performance status ≥ 60%. Patients were excluded if they were receiving other investigational agents or if they had a history of adverse reactions to compounds with similar chemical or biologic composition to capecitabine or bevacizumab, active infection with hepatitis B or C, or HIV, or other known malignancy within the past 2 years. To continue on the trial after resection was performed, patients were required to have histologically confirmed tumor recurrence (one patient with radiation necrosis was removed from the trial at this stage).
The treatment regimen began with capecitabine in the preoperative setting (5-7 days prior to surgery) with the final pre-operative dose the day of surgery. Post-operatively, capecitabine was resumed no sooner than 10 days after surgery after clearance from the surgical team and was given on days 1-28 in 28-day cycles. Bevacizumab was started on cycle 2 of capecitabine in the standard doses of 10 mg/kg IV on days 1 (± 3 days) and 15 (± 3 days) of each cycle. Magnetic resonance imaging was performed every 8 weeks. Treatment was continued until progressive disease according to RANO (Response Assessment in Neuro-oncology) criteria.
Dose escalation took place with the following doses of capecitabine: 150 mg bid (dose level 1), 300 mg bid (dose level 2), and 450 mg bid (dose level 3). As this trial was for patients with recurrent GBM, bevacizumab was included in addition to the low-dose capecitabine so that patients also received standard-of-care therapy (this combination at full doses has been proven to be well tolerated 45 ).
The primary endpoint of the study was the degree of reduction in the concentration of circulating Table 2 for the full study calendar.
As a reference group for correlative studies, a secondary cohort of newly diagnosed GBM patients who were untreated prior to surgery was followed over time, with PBPD assays performed at similar time intervals including on the day of surgery, 2 weeks post-surgery, and every 2 months.
These patients were the same as those previously analyzed and reported by our group 13 . To analyze changes in the tumor microenvironment that occur in response to the 7-day pre-operative capecitabine treatment, three newly diagnosed GBM tumor samples and one recurrent GBM tumor sample were obtained via the Cleveland Clinic Brain Tumor Tissue Bank.
Study Assessment:
Clinical Outcomes Analysis: Data collection and analysis were performed at Cleveland Clinic in May 2019. Demographic, clinical, and molecular pathology characteristics of each patient were obtained from the electronic health record and trial database. PFS was defined as the time from trial enrollment until the diagnosis of progression, and overall survival was defined as the time from initial histopathologic diagnosis until date of death.
Peripheral Blood Analysis: Peripheral blood analysis was performed at the Cleveland Clinic between 2017 and 2019, with flow cytometry performed as previously described 13 . In brief, peripheral blood mononuclear cells were isolated from whole blood via Ficoll gradient. All samples were processed less than twenty-four hours post-blood draw and then frozen in freezing medium for storage. Staining and analysis were performed using standard protocols previously described, with MDSCs marked by CD11b + , CD33 + , and HLA-DR -/lo and then further subdivided into granulocytic MDSCs (CD15 + ) and monocytic MDSCs (CD14 + ) 13, 24 . T regulatory cells were gated as CD3 + , CD4 + , CD25 + , and CD127 -, as previously described 13 . CD8 + T cells were gated on CD3 + , CD8 + , and CD4 -. Concentrations of blood MDSCs, immune cells, and relevant secreted factors were measured at baseline, pre-and post-op, and after the addition of bevacizumab.
Tumor Tissue Analysis: Analysis of tumor tissue was performed cooperatively at the Cleveland Clinic and University of California Los Angeles (UCLA) in 2018. Tumor tissue samples were collected during surgery when extra tissue was safely available and was not obtained for all patients. Upon receiving tissue samples, tumors were digested in collagenase IV (STEMCELL Technologies) for 1 hour at 37°C before being mechanically dissociated via passage through a 40 µM filter. After dissociation, the single cell suspension was washed in cold RPMI medium before being counted and frozen in freezing medium for future use. Samples were then sent to UCLA, where CyTOF analysis was performed as previously described 13 , except analysis was performed only on the CD45+ fraction of the events collected. FCS files were normalized between runs using beads and the Nolan lab normalizer 46 . Analysis tools were used in R following the methods described by Nowicka et al. 47 
Statistics
Clinical study oversight
The clinical trial and retrospective study protocols were approved by the Institutional Review There are two patients still on the trial receiving treatment. Table 3 . Treatment-related adverse events that were graded as possibly, probably, or definitely related to the treatment (capecitabine + bevacizumab). There were no Grade 4 or 5 events. Utilizing patient tumor CyTOF data, a machine-learning approach identified a reduction in a signature for immune cell exhaustion in the tumors of capecitabine-treated patients. From the CyTOF data, a decision tree was generated using the CytoDx R package (A). The first node of the decision tree is highlighted, identifying the initial finding of 76% of patients with a lower level of CTLA-4+ cells. Multidimensional tSNE modeling of the total CD45+ cells from the tumors of untreated and treated patients colored by CTLA-4 expression levels identifies the clusters with a reduction in CTLA-4 upon treatment (B). Manual gating of the CyTOF data highlighted the quantitative differences in CTLA-4+ lymphocytes in the tumors of patients treated with capecitabine (C). Further manual gating for the final subset of CTLA-4-cells identified by the decision tree revealed a unique population of CTLA-4+, PD-1+ macrophages that were suppressed upon capecitabine treatment (D). Treatment-Related Adverse Events (n =11 patients) 
Figure Legends
